Boult Wade Tennant
Bulletins » The UPC in numbers – June 2023 to December 2024

The Unified Patent Court (UPC) has recently released its latest update on the case load of the Court* since it commenced operations in June 2023.

In the intervening period the Court of First Instance (CFI) has now heard a total of 635 cases, up from 503 cases in October 2024. Some key takeaways from the lifespan of the UPC are highlighted below.

Infringement actions: 239 cases filed before the CFI have been infringement actions. These have been heard across a variety of local divisions across Europe, with the majority in Germany (81 in Munich, 51 in Dusseldorf, 32 in Mannheim and 20 in Hamburg). Paris (14 actions), Milan (a significant increase up to 13 actions) and the Hague (12 actions) have continued to see steady use while the Nordic Baltic regional division (seven actions) Brussels (two) and Helsinki, Copenhagen, Vienna, and Paris central (one each) have seen smaller change since October.

Counterclaims: 251 counterclaims for revocation have been filed with the Court’s local and regional divisions. As previously reported, this might be a slightly misleading figure as the counterclaims for revocation come from 132 individual infringement actions.

Types of actions: Infringement actions continue to be the most common use-case for the court. Of the 239 heard so far, 132 have been with a counterclaim for revocation and 107 without counterclaim. The Court of First Instance has received 62 applications for provisional measures. Stand-alone Revocation actions have been heard 55 times, with 40 revocation actions heard in Paris Central, eight in Munich and seven in Milan Central Division – more than doubling the total heard in the latter since October 2024.

Language: English remains the most commonly-used language for the court, being the language of 53% of cases, with 39% of cases being held in German, a slight decrease on the October figure (42%). French (4%), Italian (2%) Dutch (1%) and now Danish (1%) have seen more marginal use.

Appeals: The Court of Appeal has continued to be busy, with 27 appeals under RoP220.1 (litera a or b); 35 appeals under RoP220.1 (litera c) and 63 appeals under RoP220.2 to date. Additionally, there has now also been one appeal heard under RoP221.

The Court of Appeal has also received 15 requests for discretionary review, 15 applications for suspensive effect and 25 applications for an order for expedition of an appeal. The first application for rehearing under RoP245 has also been filed.

IPC classes: Class H is still the most prevalent class seen before the CFI, with 85 infringement actions, 61 counterclaims and 13 revocation actions. Class A comes next (with 52, 26 and 24 respectively) while Class G (with a marginal increase to 39, 20 and two) and Class B (33, 15 and six) follow closely behind. Class C (13, seven and six), Class E (11, five and two) and F  (five, four and two) have seen smaller change since October. Class D has still only seen a single infringement action thus far.

*Figures correct up to 1 January 2025.

Meet our UPC representatives.

Relevant sectors
Aerospace
  • Commercial aviation
  • Defence and security
  • Space and satellites
  • Unmanned aerial vehicles
Artificial Intelligence and Machine Learning
Automotive
  • Autonomous vehicles
  • Electric vehicles
  • Engines
Biotechnology
  • Antibody engineering
  • Antibody manufacture and formulation
  • Bioinformatics
  • Biosimilars
  • Drug delivery
  • Gene editing (e.g. CRISPR)
  • Genomic and molecular tools and methods
  • GM crops
  • Immuno-oncology (e.g. checkpoint inhibitors; modified T cells)
  • Next generation sequencing
  • Nucleic acid synthesis
  • Personalised medicine/disease biomarkers
  • Recombinant protein production and purification
  • Stem cell therapies
  • Supplementary protection certificates (SPCs)
  • Synthetic biology
  • Therapeutic antibodies
  • Vaccinology (e.g. viral vectors; mRNA vaccines)
  • Women’s health products
Chemicals
  • Agrochemicals
  • Catalysts
  • Dispersions and colloids
  • Lubricants
  • Polymers and plastics
Communications and Networks
  • Cloud computing
  • Internet of things (IOT)
  • Oceanography, marine
  • Wired and wireless networks
Computing and Software
  • Artificial intelligence and machine learning
  • Bioinformatics
  • Blockchain and distributed ledgers
  • Communications and networks
  • Computer games
  • Data and software security, cryptography and digital rights management (DRM)
  • Data management and storage, databases and data compression
  • Digital assistants, virtual assistants and software agents
  • Fintech and adtech
  • Machine vision
  • Metaverse, virtual reality (VR) and augmented reality (AR)
  • Motor capture
  • Multimedia, audio/video processing and animation
  • Natural language processing
  • Quantum computing
  • Robotic process automation
  • Search engines
  • Signal processing
  • Software applications and systems, mobile applications, user interfaces
Consumer Goods and Retail
  • Anti-counterfeit devices
  • Beauty
  • Fashion
  • Health, fitness and sport
  • Household goods
  • Luxury goods
  • Moda
  • Retail
Electronics and Electrical Devices
  • Computer and IT architecture and system design
  • Medical devices
  • Optics
  • Restaurants and bars
  • Robotics
  • Scientific instruments
  • Semiconductor devices
  • Testing systems, control systems, signal processing
  • Travel and leisure
  • Wearable tech and human interfaces
Energy and Green Technologies
  • Biofuels
  • Clean air
  • Fuel cells and battery technology
  • Renewables and recycling
  • Solar power
  • Water, oil and gas, nuclear, fusion, fission
  • Wind turbines
Food and Beverage
  • Beverages
  • Nutrition
  • Retail
Industrial Manufacturing and Processing
  • Packaging
  • Polymers and plastics
  • Printing tech
  • Additive manufacturing
  • Coatings
  • Construction
Materials
  • Advanced materials
  • Composite materials
  • Metallurgy and alloys
  • Nanotechnology
Medical Devices and Diagnostics
  • Artificial intelligence
  • Devices
  • Diagnostic instruments
  • Digital health
  • Drug delivery
  • Immuno-oncology
  • In vitro diagnostics
  • Medtech
Pharmaceuticals
  • Diagnostics
  • Drug delivery
  • Generic market entry
  • Medicinal chemistry
  • Methods of production and synthesis
  • Personalised medicine/disease biomarkers
  • Pharmaceutical formulations
  • Pharmaceuticalsceutical formulations
  • Polymorphs
  • Small molecule pharmaceuticals
  • Supplementary protection certificates (SPCs)
Trade Marks
  • Consumer goods
  • Cosmetics and perfumery
  • Financial services
  • Mechanical engineering
  • Mechanical products
  • Services
  • Telecommunications
Relevant sectors